ENZON AND MICROMET END RESEARCH COLLABORATION

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) and Micromet AG (private) today announced an agreement to end the companies' collaboration to identify and develop antibody-based therapeutics for the treatment of inflammatory and autoimmune diseases. The termination was jointly agreed in consequence to Enzon's efforts to redirect its investments to projects strategically aligned with its near- and long-term business objectives, including an increased focus on cancer.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1113661XSL_NEWSML_TO_NEWSML_WEB.xml)